NCT02743364View on ClinicalTrials.gov

Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

October 14, 2019

Study Completion Date

May 11, 2022

Conditions
Acute Pancreatitis
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Simvastatin

Given PO

Trial Locations (5)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

90027

Kaiser Permanente Los Angeles Medical Center, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

91188

Southern California Permanente Medical Group, Pasadena

94304

Stanford Cancer Institute Palo Alto, Palo Alto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis | Biotech Hunter | Biotech Hunter